EPZM Epizyme, Inc. Stock Quote

EPZM [NASD]

Index	-	P/E	-	EPS (ttm)	-2.14	Insider Own	0.50%	Shs Outstand	144.20M	Perf Week	53.61%
Market Cap	243.15M	Forward P/E	-	EPS next Y	-1.15	Insider Trans	-	Shs Float	124.73M	Perf Month	250.00%
Income	-236.40M	PEG	-	EPS next Q	-0.34	Inst Own	93.20%	Short Float	8.79%	Perf Quarter	26.72%
Sales	38.50M	P/S	6.32	EPS this Y	-6.60%	Inst Trans	64.51%	Short Ratio	3.21	Perf Half Y	-42.35%
Book/sh	-0.17	P/B	-	EPS next Y	23.70%	ROA	-73.50%	Target Price	5.12	Perf Year	-82.31%
Cash/sh	1.21	P/C	1.22	EPS next 5Y	38.00%	ROE	-	52W Range	0.41 - 8.52	Perf YTD	-41.20%
Dividend	-	P/FCF	-	EPS past 5Y	-4.90%	ROI	-135.80%	52W High	-82.69%	Beta	0.37
Dividend %	-	Quick Ratio	5.80	Sales past 5Y	36.10%	Gross Margin	73.30%	52W Low	258.92%	ATR	0.11
Employees	250	Current Ratio	5.90	Sales Q/Q	14.50%	Oper. Margin	-	RSI (14)	84.02	Volatility	5.53% 13.25%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	44.20%	Profit Margin	-	Rel Volume	0.70	Prev Close	1.47
Shortable	Yes	LT Debt/Eq	-	Earnings	May 10 BMO	Payout	-	Avg Volume	3.41M	Price	1.48
Recom	2.00	SMA20	74.35%	SMA50	113.87%	SMA200	-36.25%	Volume	2,227,739	Change	0.34%

Jun-28-22

Downgrade

Cowen

Outperform → Market Perform

$1.50

Jun-27-22

Downgrade

Wedbush

Outperform → Neutral

May-07-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

$12 → $16

Apr-23-21

Resumed

Cowen

Outperform

$14

Mar-31-21

Initiated

Credit Suisse

Outperform

$13

Feb-25-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$14

Dec-21-20

Downgrade

Jefferies

Buy → Hold

$14

Apr-01-20

Downgrade

Oppenheimer

Outperform → Perform

Mar-04-20

Initiated

Barclays

Overweight

$33

Feb-25-20

Reiterated

H.C. Wainwright

Buy

$25 → $36

Jan-24-20

Downgrade

SVB Leerink

Outperform → Mkt Perform

Dec-06-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

May-30-19

Resumed

Citigroup

Buy

Jan-07-19

Upgrade

Leerink Partners

Mkt Perform → Outperform

Sep-07-18

Resumed

Morgan Stanley

Equal-Weight

Jul-03-18

Downgrade

Leerink Partners

Outperform → Mkt Perform

Jan-24-18

Resumed

Jefferies

Buy

$25

Jan-10-18

Initiated

Morgan Stanley

Overweight

$20

Nov-02-17

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$20 → $16

Sep-20-17

Initiated

Jefferies

Buy

$23

Jun-29-22 11:51AM	Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More Zacks
Jun-27-22 02:17PM	Epizyme shares soar 60% on acquisition news American City Business Journals +55.14%
12:24PM	Why Epizyme Stock Is Soaring Today Motley Fool
11:00AM	Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen Zacks
06:45AM	Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why Benzinga
02:12AM	Ipsen to acquire U.S.-based Epizyme for $247 million. MarketWatch
01:01AM	Ipsen to acquire Epizyme, expanding its portfolio in oncology Business Wire
Jun-09-22 11:30AM	Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report? Zacks -7.85%
Jun-02-22 07:00AM	Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting Business Wire +12.29%
May-17-22 07:00AM	Epizyme To Participate in H.C. Wainwright Global Investment Conference Business Wire +12.15%
May-11-22 02:28PM	Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates Zacks -21.16%
May-10-22 08:15AM	Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM	Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update Business Wire
May-09-22 06:25PM	Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates Zacks -6.11%
May-03-22 12:00PM	Epizyme (EPZM) Upgraded to Buy: What Does It Mean for the Stock? Zacks
07:26AM	What Kind Of Shareholders Own Epizyme, Inc. (NASDAQ:EPZM)? Simply Wall St.
07:00AM	Epizyme Announces Date of First Quarter 2022 Financial Results Business Wire
Apr-19-22 12:23PM	Fore Biotherapeutics names new CEO American City Business Journals
Apr-14-22 10:06AM	10 Pharmaceutical Stocks to Buy Now According to Billionaire Kerr Neilson Insider Monkey -6.35%
Apr-06-22 07:00AM	Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -7.08%
Mar-31-22 11:30AM	Why Is Epizyme (EPZM) Down 29.7% Since Last Earnings Report? Zacks
Mar-17-22 09:47AM	Voyager Therapeutics (VYGR) Surges 12.1%: Is This an Indication of Further Gains? Zacks +6.11%
Mar-16-22 12:00PM	Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why Zacks +9.17%
Mar-15-22 07:00AM	Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update Business Wire
Mar-02-22 11:22AM	Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag Zacks
08:00AM	Epizyme to Participate in Upcoming Healthcare Conferences in March Business Wire
Mar-01-22 09:05AM	Epizyme (EPZM) Reports Q4 Loss, Misses Revenue Estimates Zacks +6.71%
07:00AM	Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Business Wire
Feb-22-22 07:00AM	Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results Business Wire
Feb-17-22 08:40AM	Is a Surprise Coming for Epizyme (EPZM) This Earnings Season? Zacks -8.70%
Feb-15-22 03:01PM	Epizyme (EPZM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks +7.28%
Feb-03-22 03:25PM	Why Shares of Epizyme Soared 32.1% This Week Motley Fool
Feb-01-22 10:00AM	Down 54.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Epizyme (EPZM) Zacks
Jan-28-22 03:36PM	Epizyme (EPZM) Stock Dives on Public Offering of Common Stock Zacks
Jan-27-22 06:27PM	Why Epizyme Stock Plummeted by 44% Today Motley Fool -44.21%
09:17AM	Epizyme Raises $85M Via Equity Issued At 21% Discount Benzinga
02:12AM	Epizyme Announces Pricing of Public Offering of Common Stock Business Wire
Jan-26-22 04:01PM	Epizyme Announces Proposed Public Offering of Common Stock Business Wire -5.47%
Jan-10-22 07:00AM	Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates Business Wire +7.11%
Jan-07-22 01:38PM	Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ... GuruFocus.com
05:50AM	Bullish Epizyme, Inc. (NASDAQ:EPZM) investors are yet to receive a pay off on their US$500k bet Simply Wall St.
Dec-12-21 09:00AM	Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting Business Wire
Dec-11-21 09:00AM	Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Companys SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting Business Wire
Dec-02-21 06:30AM	Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting Business Wire +5.98%
Nov-18-21 06:30AM	Epizyme Announces Updates to Its Board of Directors Business Wire -6.59%
Nov-12-21 08:00AM	Epizyme to Participate in Jefferies London Healthcare Conference Business Wire
Nov-10-21 11:03AM	Epizyme (EPZM) Q3 Loss Wider Than Expected, Revenues Up Zacks
Nov-09-21 03:30PM	Epizyme, inc (EPZM) Q3 2021 Earnings Call Transcript Motley Fool
07:45AM	Epizyme (EPZM) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:30AM	Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update Business Wire
Nov-05-21 07:00AM	Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-04-21 06:30AM	Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414 Business Wire
Nov-02-21 06:30AM	Epizyme Announces Date of Third Quarter 2021 Financial Results Business Wire
Nov-01-21 08:00AM	Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making Business Wire +5.71%
Oct-29-21 03:00PM	Will Epizyme (EPZM) Report Negative Q3 Earnings? What You Should Know Zacks -5.83%
Oct-23-21 06:08AM	15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors Insider Monkey
Oct-14-21 09:14AM	Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe Zacks
Oct-07-21 07:00AM	Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-14-21 06:30AM	Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress Business Wire
Sep-08-21 11:30AM	Why Is Epizyme (EPZM) Up 3.8% Since Last Earnings Report? Zacks
Aug-20-21 08:00AM	Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-10-21 03:40PM	Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates Zacks -6.14%
07:16AM	Industry Analysts Just Made A Captivating Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts Simply Wall St.
Aug-09-21 06:30PM	Epizyme, inc (EPZM) Q2 2021 Earnings Call Transcript Motley Fool -9.43%
04:55PM	Why Epizyme Is Getting Crushed Today Motley Fool
08:45AM	Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:35AM	Epizyme Announces CEO Succession Business Wire
07:30AM	Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire
Aug-08-21 08:00PM	HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China GlobeNewswire
08:00PM	Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China Business Wire
Aug-03-21 04:01PM	Epizyme Announces Date of Second Quarter 2021 Financial Results Business Wire
Jul-27-21 06:48PM	Here is What Hedge Funds Think About Epizyme Inc (EPZM) Insider Monkey
03:03PM	Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-02-21 08:41AM	Why Epizyme Stock Is Falling This Week Motley Fool -5.91%
Jun-28-21 04:15AM	Epizyme, Inc. (NASDAQ:EPZM) Insiders Increased Their Holdings Simply Wall St.
Jun-16-21 06:30AM	Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients Business Wire
Jun-14-21 12:59PM	Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models Benzinga
May-25-21 06:30AM	Epizyme to Participate in Jefferies Virtual Healthcare Conference Business Wire
May-12-21 04:01PM	Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June Business Wire
May-07-21 05:30PM	Epizyme Inc (EPZM) Q1 2021 Earnings Call Transcript Motley Fool +21.73%
08:44AM	SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug MarketWatch
07:24AM	Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates Zacks
May-06-21 08:05AM	Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates Zacks -9.44%
06:30AM	Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results Business Wire
Apr-29-21 06:30AM	Epizyme Announces Date of First Quarter 2021 Financial Results Business Wire
Apr-01-21 12:13PM	2 Strong Buy Stocks Insiders Are Snapping Up TipRanks
Mar-25-21 11:30AM	Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound? Zacks
Mar-02-21 12:00PM	Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Companys Strategic Vision Call Business Wire
Feb-28-21 01:34AM	The Epizyme, Inc. (NASDAQ:EPZM) Analysts Have Been Trimming Their Sales Forecasts Simply Wall St.
Feb-25-21 10:03AM	Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2021 Benzinga -5.20%
Feb-24-21 06:30AM	Epizyme to Host Strategic Vision Call on March 2, 2021 Business Wire
Feb-23-21 08:00PM	Epizyme Inc (EPZM) Q4 2020 Earnings Call Transcript Motley Fool
10:31AM	CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
10:04AM	Return On Capital Employed Overview: Epizyme Benzinga
07:24AM	Epizyme: Q4 Earnings Insights Benzinga
06:15AM	Epizyme, Inc. to Host Earnings Call ACCESSWIRE
Feb-20-21 09:36AM	The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings Benzinga
Feb-16-21 06:30AM	Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences Business Wire
Jan-25-21 07:52AM	Is Epizyme (NASDAQ:EPZM) Weighed On By Its Debt Load? Simply Wall St.
Dec-18-20 02:43PM	Is EPZM A Good Stock To Buy Now According To Hedge Funds? Insider Monkey

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kutok Jeffery	Chief Scientific Officer	Apr 11	Sale	0.90	2,741	2,467	94,563	Apr 13 05:49 PM
Beaulieu Joseph	Corporate Controller	Feb 07	Sale	1.50	222	333	28,632	Feb 09 05:43 PM
Agarwal Shefali	See Remarks	Feb 07	Sale	1.50	1,058	1,587	156,385	Feb 09 05:40 PM
Beaulieu Joseph	Corporate Controller	Feb 02	Sale	1.37	687	941	28,854	Feb 04 04:15 PM
Agarwal Shefali	See Remarks	Feb 02	Sale	1.37	2,639	3,615	157,443	Feb 04 04:15 PM
Kutok Jeffery	Chief Scientific Officer	Feb 02	Sale	1.37	2,556	3,502	97,304	Feb 04 04:15 PM
Legorreta Pablo G.	Director	Jan 31	Buy	1.50	22,666,667	34,000,000	31,833,334	Feb 01 04:17 PM
Agarwal Shefali	See Remarks	Jan 26	Sale	2.02	2,922	5,902	160,082	Jan 28 04:15 PM
Agarwal Shefali	See Remarks	Dec 06	Sale	2.93	1,780	5,215	163,004	Dec 07 07:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience